It was recently demonstrated that targeting CHK1 is therapeutically beneficial in p53 deficient cells as well as in triple negative breast cancers (TNBC), which harbor alterations in p53 at a frequency of approximately 40% of cases (14, 19, 20). This evidence concerns the gene TP53 and triple-negative breast carcinoma.